The German company #BioNTech partnered with #Pfizer to develop and test a #coronavirus vaccine known as BNT162b2. A clinical trial demonstrated that the vaccine has an efficacy rate of 95 percent in preventing Covid-19.
The SARS-CoV-2 virus is studded with proteins that it uses to enter human cells. These so-called spike proteins make a tempting target for potential vaccines and treatments.

Like the Moderna vaccine, the Pfizer-BioNTech vaccine is based on the virus’s genetic instructions for building the spike protein.
Comments